Location: Home > Pharma China Web Edition
  • search
  • go
  • Product/R&D News
    China's First COVID-19 Virus Vaccine Patent Granted to CanSino Bio 9/16/2020

    The China National Intellectual Property Administration (CNIPA) granted on September 11, 2020 what may be the first patent covering a vaccine for the COVID-19 virus. The patent published under number CN111218459B.

    The Institute of Military Medicine, Chinese Academy of Military Sciences in conjunction with CanSinoBIO, a Chinese vaccine maker, filed application CN202010193587.8 on March 18, 2020 and is entitled “A new recombinant coronavirus vaccine using human replication-deficient adenovirus as a vector.” 

    The patent is based on research earlier published in the Lancet showing their Ad5 vectored COVID-19 vaccine “is tolerable and immunogenic at 28 days post-vaccination.” Per the Wall Street Journal, China’s military has already approved the use of CanSino’s vaccine before the completion of large-scale final testing, usually known as Phase 3 trials.

  • Site map | Contact Us | Links
  • © Wicon International Group Support by: www.heightow.com